← Back to Search

Social Interaction Perceptions for Mental Illness

N/A
Recruiting
Led By Daphne J Holt, MD, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Experienced a psychotic disorder or mood disorder
Age between 18-55 years old
Must not have
Not proficient in English
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if loneliness and social isolation are linked to how someone perceives and is motivated by social interactions. The findings could help provide new targets for treatments to improve quality of life for those with serious mental illnesses.

Who is the study for?
This trial is for individuals aged 18-55 who have experienced serious mental illnesses like psychosis, schizophrenia, or mood disorders. Participants must speak English fluently and not have had any recent medication changes or acute symptoms. They can't join if they've used substances in the past 6 months, have neurological issues, MRI scan exclusions like metal implants, or severe claustrophobia.
What is being tested?
The study examines how social isolation and loneliness affect brain behavior related to social perception and motivation in people with serious mental illness. It uses EMA (Ecological Momentary Assessment) to track these experiences in real-time and their impact on daily functioning.
What are the potential side effects?
Since this trial involves assessments rather than medications or invasive procedures, there are no direct side effects from interventions. However, participants may experience discomfort discussing personal feelings of loneliness or isolation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had a psychotic or mood disorder.
Select...
I am between 18 and 55 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not fluent in English.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Characterize within-person, dynamic changes in objective isolation and loneliness
Physical health and cardiometabolic/immunological panel
Psychosocial functioning
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ecological Momentary AssessmentExperimental Treatment1 Intervention
EMA collected daily (4x/day) for two weeks

Find a Location

Who is running the clinical trial?

Boston UniversityOTHER
472 Previous Clinical Trials
9,987,706 Total Patients Enrolled
1 Trials studying Schizophrenia
461 Patients Enrolled for Schizophrenia
Massachusetts General HospitalLead Sponsor
3,015 Previous Clinical Trials
13,309,240 Total Patients Enrolled
46 Trials studying Schizophrenia
7,186 Patients Enrolled for Schizophrenia
Daphne J Holt, MD, PhDPrincipal InvestigatorMassachusetts General Hospital

Media Library

Ecological Momentary Assessment Clinical Trial Eligibility Overview. Trial Name: NCT04940663 — N/A
Schizophrenia Research Study Groups: Ecological Momentary Assessment
Schizophrenia Clinical Trial 2023: Ecological Momentary Assessment Highlights & Side Effects. Trial Name: NCT04940663 — N/A
Ecological Momentary Assessment 2023 Treatment Timeline for Medical Study. Trial Name: NCT04940663 — N/A
~47 spots leftby Jun 2026